Key facts
- This page summarizes Jeffrey Eisele's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2024, 16:03.
Jeffrey Eisele - 23 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- APLS
- Reported as of
- 23 Jan 2024
- Net transaction value
- -$469,905
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2024, 16:03:55 UTC
- Prior SEC filing
- 23 Jan 2024
- Next SEC filing
- 31 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Jeffrey Eisele
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Eisele filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 24 Jan 2024.
Change
- Previous filing in this sequence was filed on 23 Jan 2024.
- Current net transaction value: -$469,905.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Sale
- Transaction value
- $469,905
- Shares
- -7,378
- Change %
- -11%
- Price
- $63.69
- Shares after
- 58,458
- Date
- 23 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 1 footnote
Footnote F1
This is a scheduled sale from an established 10b5-1 plan.